These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 3192383)
1. Evaluation of cardiotoxicity of a new anthracycline derivative: 4'-deoxy-4'-iodo-doxorubicin. Villani F; Galimberti M; Lanza E; Rozza A; Favalli L; Poggi P Invest New Drugs; 1988 Sep; 6(3):173-8. PubMed ID: 3192383 [TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicity and cytotoxicity of the anthracycline analog 4'-deoxy-4'-iodo-doxorubicin. Danesi R; Bernardini N; Agen C; Costa M; Macchiarini P; Della Torre P; Del Tacca M Toxicology; 1991; 70(2):243-53. PubMed ID: 1763418 [TBL] [Abstract][Full Text] [Related]
3. Reduced cardiotoxicity and increased cytotoxicity in a novel anthracycline analogue, 4'-amino-3'-hydroxy-doxorubicin. Danesi R; Bernardini N; Agen C; Costa M; Zaccaro L; Pieracci D; Malvaldi G; Del Tacca M Cancer Chemother Pharmacol; 1992; 29(4):261-5. PubMed ID: 1472260 [TBL] [Abstract][Full Text] [Related]
4. Dissociation between in vitro cytotoxicity and in vivo cardiotoxicity of two new anthracyclines: 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin and 4'-deoxy-4'-iodo-doxorubicin. Pinna A; Agen C; Di Paolo A; Innocenti F; Nardini D; Danesi R; Del Tacca M J Environ Pathol Toxicol Oncol; 1994; 13(1):25-31. PubMed ID: 7823290 [TBL] [Abstract][Full Text] [Related]
5. [The prevention of the myocardial toxicity of doxorubicin with superoxide dismutase]. Villani F; Galimberti M; Favalli L; Rozza A; Lanza E; Poggi P G Ital Cardiol; 1991 Jun; 21(6):633-41. PubMed ID: 1743445 [TBL] [Abstract][Full Text] [Related]
6. Comparison of cardiotoxicity of pirarubicin, epirubicin and doxorubicin in the rat. Hirano S; Wakazono K; Agata N; Iguchi H; Tone H Drugs Exp Clin Res; 1994; 20(4):153-60. PubMed ID: 7813387 [TBL] [Abstract][Full Text] [Related]
7. Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Danesi R; Marchetti A; Bernardini N; La Rocca RV; Bevilacqua G; Del Tacca M Cancer Chemother Pharmacol; 1990; 26(6):403-8. PubMed ID: 2171795 [TBL] [Abstract][Full Text] [Related]
8. Reducing doxorubicin cardiotoxicity in the rat using deferred treatment with ADR-529. Agen C; Bernardini N; Danesi R; Della Torre P; Costa M; Del Tacca M Cancer Chemother Pharmacol; 1992; 30(2):95-9. PubMed ID: 1600601 [TBL] [Abstract][Full Text] [Related]
9. Relationship between doxorubicin-induced ECG changes and myocardial alterations in rats. Villani F; Monti E; Piccinini F; Favalli L; Lanza E; Rozza Dionigi A; Poggi P Tumori; 1986 Jun; 72(3):323-9. PubMed ID: 3739010 [TBL] [Abstract][Full Text] [Related]
10. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione. Villani F; Galimberti M; Zunino F; Monti E; Rozza A; Lanza E; Favalli L; Poggi P Cancer Chemother Pharmacol; 1991; 28(5):365-9. PubMed ID: 1914080 [TBL] [Abstract][Full Text] [Related]
11. Trifluoperazine does not affect doxorubicin cardiotoxicity in the rat. Villani F; Monti E; Piccinini F; Favalli L; Rozza Dionigi A; Lanza E; Poggi P Anticancer Res; 1988; 8(4):659-63. PubMed ID: 3178155 [TBL] [Abstract][Full Text] [Related]
12. [The effect of superoxide dismutase and catalase on the delayed toxicity of doxorubicin]. Villani F; Galimberti M; Poggi P; Rozza A; Lanza E; Favalli L; Scavini C Cardiologia; 1992 Oct; 37(10):709-11. PubMed ID: 1296877 [TBL] [Abstract][Full Text] [Related]
14. Effect of ICRF-187 pretreatment against doxorubicin-induced delayed cardiotoxicity in the rat. Villani F; Galimberti M; Monti E; Cova D; Lanza E; Rozza-Dionigi A; Favalli L; Poggi P Toxicol Appl Pharmacol; 1990 Feb; 102(2):292-9. PubMed ID: 2105541 [TBL] [Abstract][Full Text] [Related]
15. Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Jensen RA; Acton EM; Peters JH Cancer Res; 1984 Sep; 44(9):4030-9. PubMed ID: 6744318 [TBL] [Abstract][Full Text] [Related]
16. Effect of flunarizine on the delayed cardiotoxicity of doxorubicin in rats. Villani F; Galimberti M; Monti E; Piccinini F; Poggi P; Lanza E; Rozza A; Favalli L Pharmacol Res; 1991 Feb; 23(2):195-202. PubMed ID: 2062794 [TBL] [Abstract][Full Text] [Related]
17. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. Cirillo R; Sacco G; Venturella S; Brightwell J; Giachetti A; Manzini S J Cardiovasc Pharmacol; 2000 Jan; 35(1):100-8. PubMed ID: 10630739 [TBL] [Abstract][Full Text] [Related]
18. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Herman EH; Zhang J; Rifai N; Lipshultz SE; Hasinoff BB; Chadwick DP; Knapton A; Chai J; Ferrans VJ Cancer Chemother Pharmacol; 2001 Oct; 48(4):297-304. PubMed ID: 11710630 [TBL] [Abstract][Full Text] [Related]
19. Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. Jensen RA; Acton EM; Peters JH J Cardiovasc Pharmacol; 1984; 6(1):186-200. PubMed ID: 6199603 [TBL] [Abstract][Full Text] [Related]
20. General and cardiac toxicity of doxorubicin-loaded gelatin nanoparticles. Leo E; Arletti R; Forni F; Cameroni R Farmaco; 1997; 52(6-7):385-8. PubMed ID: 9372590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]